

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	75,183	99.8%	58,643	99.8%	8,059	99.8%	7,338	100.0%	246	100.0%	7,005	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	63,846	84.8%	49,203	83.7%	7,070	87.5%	6,658	90.7%	215	87.4%	6,014	85.7%
Cribriform carcinoma <i>in situ</i> (8201/2)	6,409	8.5%	4,826	8.2%	748	9.3%	735	10.0%	21	8.5%	615	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	5,073	6.7%	4,042	6.9%	477	5.9%	479	6.5%	18	7.3%	419	6.0%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	22,740	30.2%	17,793	30.3%	2,508	31.0%	2,074	28.3%	78	31.7%	2,106	30.0%
Comedocarcinoma <i>in situ</i> (8501/2)	6,030	8.0%	4,689	8.0%	614	7.6%	641	8.7%	34	13.8%	562	8.0%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,156	1.5%	790	1.3%	202	2.5%	142	1.9%	-	-	114	1.6%
Noninfiltrating intracystic carcinoma(8504/2)	264	0.4%	171	0.3%	38	0.5%	52	0.7%	-	-	27	0.4%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,352	1.8%	1,064	1.8%	168	2.1%	105	1.4%	-	-	130	1.9%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	20,649	27.4%	15,703	26.7%	2,305	28.5%	2,395	32.6%	58	23.6%	2,028	28.9%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,560	11.4%	7,239	12.3%	686	8.5%	441	6.0%	26	10.6%	755	10.8%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,538	11.3%	7,220	12.3%	683	8.5%	441	6.0%	26	10.6%	754	10.7%
Lobular CIS ^f with other CIS ^f (8524/2)	22	0.0%	19	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,261	3.0%	1,819	3.1%	239	3.0%	175	2.4%	-	-	188	2.7%
Other adenocarcinomas ^g	510	0.7%	378	0.6%	64	0.8%	62	0.8%	-	-	48	0.7%
Other <i>in situ</i> histologies ^h	137	0.2%	108	0.2%	20	0.2%	-	-	-	-	-	-
Total	75,320	100.0%	58,751	100.0%	8,079	100.0%	7,341	100.0%	246	100.0%	7,018	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.